scholarly journals Drug-induced lupus erythematosus associated with donepezil: a case report

2015 ◽  
Vol 44 (6) ◽  
pp. 1062-1063 ◽  
Author(s):  
Ciro Manzo ◽  
Salvatore Putignano
Keyword(s):  
Case Report ◽  
Lupus Erythematosus ◽  
Drug Induced

scholarly journals Drug-Induced Gingival Overgrowth in an 8-Year-Old Girl: A Case Report

2021 ◽  
Vol 13 (3) ◽  
pp. 109-112
Author(s):  
Parviz Torkzaban ◽  
Amir Talaie
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Case Report ◽  
Autoimmune Disease ◽  
Lupus Erythematosus ◽  
Immunological Tolerance ◽  
Systemic Autoimmune Disease ◽  
Channel Blockers ◽  
Systemic Lupus ◽  
Drug Induced ◽  
Gingival Overgrowth

Systemic lupus erythematosus is a systemic autoimmune disease that involves multi organs. Genetic, endocrine, immunological, and environmental factors influence the loss of immunological tolerance against self-antigens leading to the formation of pathogenic autoantibodies that cause tissue damage through multiple mechanisms. The gingival overgrowth can be caused by three factors: noninflammatory, hyperplastic reaction to the medication; chronic inflammatory hyperplasia; or a combined enlargement due to chronic inflammation and drug-induced hyperplasia. Drug-Induced Gingival Overgrowth is associated with the use of three major classes of drugs, namely anticonvulsants, calcium channel blockers, and immunosuppressants. Due to recent indications for these drugs, their use continues to grow.

Drug-Induced Lupus Erythematosus Presenting With Cardiac Tamponade: A Case Report and Literature Review

2014 ◽  
Vol 30 (2) ◽  
pp. 247.e11-247.e12 ◽  
Author(s):  
David T. Harnett ◽  
Harnahalli B. Chandra-Sekhar ◽  
Sean F. Hamilton
Keyword(s):  
Case Report ◽  
Literature Review ◽  
Cardiac Tamponade ◽  
Lupus Erythematosus ◽  
Drug Induced

scholarly journals Lupus Cerebritis Refractory to Guideline-Directed Therapy: A Case Report

2021 ◽  
Vol 9 ◽  
pp. 232470962110087
Author(s):  
Suman Rao ◽  
Akhila Sunkara ◽  
Ashwini Ashwath ◽  
Nimisha Srivastava ◽  
Emily Albert
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Case Report ◽  
Lupus Erythematosus ◽  
Neuropsychiatric Symptoms ◽  
Antipsychotic Agent ◽  
Systemic Lupus ◽  
Drug Induced ◽  
Multiple Organs ◽  
Organ Systems ◽  
Current Guidelines

Systemic lupus erythematosus is an autoimmune disease that affects multiple organs and organ systems, subsequently requiring an elaborate regimen for management. We present the case of a 63-year-old female who developed unrelenting symptoms of drug-induced lupus, which persisted even after the offending agent was withdrawn, unmasking her underlying systemic lupus erythematosus. She continued to develop neuropsychiatric symptoms, including mania and hallucinations, which complicated the management of her disease. After exhausting the bank of anti-inflammatory and immunomodulators recommended by current guidelines, we found that a combination of rituximab infusions with thiothixene, an antipsychotic agent, significantly improved our patient’s neuropsychiatric symptoms. Further research should be conducted to determine the efficacy of rituximab in the treatment of resistant lupus cerebritis, and to validate the use of thiothixene in the management of neuropsychiatric symptoms secondary to lupus.

scholarly journals ANA-Negative Hydralazine-Induced Pericardial Effusion

2017 ◽  
Vol 2017 ◽  
pp. 1-3 ◽  
Author(s):  
Vicken Zeitjian ◽  
Azar Mehdizadeh
Keyword(s):  
Adverse Effect ◽  
Case Report ◽  
Pericardial Effusion ◽  
Literature Review ◽  
Causative Agent ◽  
Lupus Erythematosus ◽  
Drug Induced

This case describes a patient with pericardial effusion as a phenomenon of the drug-induced lupus erythematosus (DILE) syndrome due to hydralazine. The relevance of this case report lies in the fact that although hydralazine has been a known causative agent of DILE, its presentation may involve a negative anti-nuclear antibody (ANA) study. Pericardial effusion is a documented adverse effect as a result of hydralazine use. It is typically common to screen for DILE with the serum ANA test prior to proceeding to more costly and specific tests (i.e., anti-histone antibody). As per our literature review, this is the second case of hydralazine causing DILE with a negative ANA. As in our case, although the screening serum ANA is the initial next best step for suspicion of DILE by hydralazine, it is important to consider the diagnosis without ANA positivity.

DRUG INDUCED LUPUS ERYTHEMATOSUS?A CASE REPORT

1978 ◽  
Vol 19 (1) ◽  
pp. 31-32 ◽  
Author(s):  
J. D. Adams
Keyword(s):  
Case Report ◽  
Lupus Erythematosus ◽  
Drug Induced

scholarly journals Episcleritis Related to Drug-Induced Lupus Erythematosus following Infliximab Therapy: A Case Report

2011 ◽  
Vol 2011 ◽  
pp. 1-3 ◽  
Author(s):  
Irini P. Chatziralli ◽  
Evgenia Kanonidou ◽  
Alexandros Chatzirallis ◽  
Prodromos Dimitriadis ◽  
Petros Keryttopoulos
Keyword(s):  
Case Report ◽  
Lupus Erythematosus ◽  
Drug Exposure ◽  
Clinical Manifestations ◽  
Infliximab Therapy ◽  
Drug Induced ◽  
Laboratory Findings ◽  
Ocular Disorders ◽  
Main Message

Drug-induced lupus erythematosus is defined as a lupus-like syndrome temporally related to continuous drug exposure which resolves after discontinuation of the offending drug. Herein, we describe a patient with distinct clinical manifestations of anti-TNF-associated DILE related to infliximab therapy. The patient exhibited clinical and laboratory findings of lupus-like illnesses as well as ocular disorders, such as episcleritis. The main message is that the symptoms of DILE should not be overlooked, although sometimes other systematic conditions may underlie them. As a result, it is very important for the clinicians to evaluate the symptoms of DILE and manage appropriately these cases.

scholarly journals Drug-induced subacute cutaneous lupus erythematosus associated with docetaxel chemotherapy: a case report

2014 ◽  
Vol 7 (1) ◽  
pp. 785 ◽  
Author(s):  
Noelle Y Wong ◽  
Laurie M Parsons ◽  
Martin J Trotter ◽  
Roger Y Tsang
Keyword(s):  
Case Report ◽  
Lupus Erythematosus ◽  
Cutaneous Lupus Erythematosus ◽  
Subacute Cutaneous Lupus Erythematosus ◽  
Drug Induced ◽  
Docetaxel Chemotherapy ◽  
Cutaneous Lupus

Endocrine malignancies and systemic lupus erythematosus: case report

2019 ◽  
Author(s):  
Nadia Ghariani Fetoui ◽  
Rima Gammoudi ◽  
Najet Ghariani ◽  
Yosra Hasni ◽  
Racha Fekih ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Case Report ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Systemic Lupus Erythematosus Case
Sign in / Sign up

Export Citation Format

Share Document